 Bennett Jones Education York University, BA, 2009, honours, cum laude University of Detroit Mercy, JD, 2014, cum laude University of Windsor, JD, 2014 Bar Admissions Ontario, 2015 Corey Yermus is engaged in a broad corporate commercial and securities practice. Overview Corey's experience involves a wide variety of transactional work including mergers and acquisitions (both in the Canadian and cross-border context), debt and equity financings (both domestic and international), public and private securities offerings, take-over bids, initial public offerings and other business combinations. As well, Corey advises clients on a diverse range of unique corporate governance, securities and compliance matters. With transactional experience in industries including agribusiness and life sciences, technology, regulated industries like consumer products, media & telecom and financial services, Corey assists clients in achieving their goals while safeguarding their interests in the complex transactional landscape. A select scope of his clients include public and private issuers (large, mid-cap as well as emerging), and foreign acquirers of Canadian public entities. Corey participates in the firm’s mentoring program. Experience • Numinus Wellness Inc., in the establishment of a shelf prospectus for proceeds of $150M. • Wellfield Technologies in its acquisition of all of the issued and outstanding common shares as well as certain other assets related to the operation of Brane Trust Company. • Field Trip Health Ltd., in the spin-out of its drug development and medical clinics businesses into two independent public companies, Reunion Neuroscience and Field Trip Health & Wellness, by plan of arrangement. The spin-out transaction was supported by a private placement financing led by Oasis Management Company. • Wellfield Technologies Inc., in its acquisition of New Bit Ventures Ltd., d/b/a Coinmama at an agreed valuation of US$50 Million • PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.), in a $14.5-million reverse takeover of PsyBio Therapeutics, Inc., a biotechnology company developing a new class of drugs intended for the potential treatment of mental health challenges and other disorders. • Seamless Logic Software Limited, in its merger with MoneyClip Inc. to create Wellfield Technologies Inc., and the listing of Wellfield on the TSX Venture Exchange which was supported by a $20-million financing, bringing the total post-money valuation of Wellfield to >$100-million. • Medicus Pharma Ltd., in its acquisition of Antev Limited, a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention episodes due to enlarged prostate, for consideration of up to approximately US$75 million. • Pyxus International, in the Canadian aspects of its US$1.2-billion recapitalization under Chapter 11 and infusion of US$400 million of fresh capital. |